Skip to main content
Clinical Trials/NCT00935116
NCT00935116
Unknown
Phase 4

Effect of the Administration of Etoricoxib on Postoperative Pain and Quality of Recovery in Patients Undergoing Thyroid Surgery

Hospital Padre Hurtado0 sites70 target enrollmentStarted: July 2009Last updated:
ConditionsAcute Pain
Interventionsetoricoxib

Overview

Phase
Phase 4
Enrollment
70
Primary Endpoint
Maximum pain scores during postoperative period

Overview

Brief Summary

The purpose of the study is evaluate the analgesic efficacy and safety profile of the Cox-2 specific analgesic Etoricoxib (arcoxia®) when administrated pre and postoperatively for controlling pain in adult patients undergoing thyroid surgery. Patients will be followed up in the immediate postoperative period, during the first postoperative (POD) day and in POD 2, 3 and 7. It is expected that with the addition of Etoricoxib, patients will experience less pain during the overall postoperative period and also a better quality of recovery when compared with the traditional analgesic regimen.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • age \>18 and \<70 years
  • body weight within normal ranges
  • ability to understand the use of pain assessment scales and the PCA device

Exclusion Criteria

  • known allergy to any of the drugs utilized
  • contraindication to opioid and non-opioid analgesic drugs
  • a history of bleeding disorders, peptic ulceration or anticoagulant use within the last month
  • pregnant or breast-feeding patients
  • history of known or suspected drug abuse or patients who had taken NSAIDs within 24 h prior to surgery

Arms & Interventions

etoricoxib

Active Comparator

G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.

G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery

Intervention: etoricoxib (Drug)

Outcomes

Primary Outcomes

Maximum pain scores during postoperative period

Time Frame: every 6 hours, 24hours,48hours,72hours.

Secondary Outcomes

  • Total amount of rescue analgesics(24hours, 48hours, 72hours.)

Investigators

Sponsor Class
Other

Similar Trials